QUESTIONS / CALIBRATED ANSWERS
Frequently asked, carefully answered
Direct answers that keep the molecule, model, and strength of evidence together.
What is NAD supplement used for?
NAD+ products and the precursors NMN and NR are marketed around energy and healthy-ageing claims. In controlled human research, NMN and NR have reliably raised blood NAD+ [2][5], and individual studies have reported selected functional or metabolic signals [2][3]. A current review finds that translation into consistent clinical benefit remains limited [1]. The intervention matters: evidence for a precursor does not automatically apply to intact oral NAD+ or compounded infusion products.
What is the downside of taking NAD+?
The main downside is uncertainty hidden by a simple name. NAD+, NMN, NR, oral supplements, and compounded infusions differ in absorption, evidence, and product oversight. Short controlled precursor trials reported reassuring tolerability within their studied settings [2][5], but they do not establish long-term safety or prove broad anti-ageing outcomes. Product variability and the weak controlled basis for infusion marketing add further uncertainty.
Does NAD cause weight gain?
The supplied research does not establish NAD+ or its precursors as a cause of weight gain. In a 10-week NMN study, muscle insulin sensitivity improved while body composition and HbA1c did not change [3]. That narrow result should not be stretched into a weight-loss or weight-gain claim. Body weight was not established here as a consistent clinical effect.
What does BPC-157 do in the body?
In experimental systems, BPC-157 activates repair-related signaling, most clearly a VEGFR2-Akt-eNOS pathway linked to new blood-vessel formation [11]. Rat studies also report gastric protection and healing [12]. Human effects remain uncertain. The current review finds only three pilot studies and no rigorous large-scale trials [9], so model-based mechanisms cannot be presented as proven injury repair in people.
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic 15-amino-acid peptide fragment, not growth hormone. Some laboratory work links it to growth-hormone-receptor signaling in tendon cells, but interacting with a pathway does not make two molecules the same. Its best-described research mechanism involves VEGFR2 and nitric-oxide signaling [11].
Does BPC-157 work immediately?
Controlled human research does not establish when or whether BPC-157 produces a therapeutic effect. Community timelines are anecdotal, not clinical evidence, and product identity is often uncertain. The only human safety pilot in this corpus involved two adults and did not test efficacy [8]. A current review describes the clinical evidence as extremely limited [9].
What does a GHK-Cu peptide do?
GHK-Cu binds copper and is studied for matrix remodeling, skin signaling, topical delivery, and hair-related formulations. Reviews describe effects on collagen-related processes and other cell programs [13][16]. The human literature is mostly small and topical, and one positive hair trial used a combination formulation rather than pure GHK-Cu [15]. This supports modest, formulation-specific language rather than a universal anti-ageing claim.
What is the difference between GHK and GHK-Cu?
GHK is the three-amino-acid peptide glycine-histidine-lysine. GHK-Cu is the complex formed when that peptide coordinates a copper ion. Copper binding changes the compound's chemistry and is central to many reported matrix and enzyme-related effects. Studies of free GHK, intact GHK-Cu, or a combination product should therefore be read as evidence about different test materials.
Is GHK-Cu peptide really anti-aging?
“Anti-aging” is broader than the evidence can carry. Small topical studies and reviews report selected skin-related signals, while laboratory analyses describe wide gene-expression effects [13][14][16]. Poor skin permeability remains a delivery challenge [13], and there is no validated human evidence here for whole-body rejuvenation. The precise reading is that GHK-Cu is an interesting topical and matrix-research compound with limited clinical depth.
What is PT-141 used for?
As bremelanotide, PT-141 is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Two Phase 3 trials support effects on desire and desire-related distress in that population [20], while the label defines contraindications and warnings [22]. Uses in men, postmenopausal women, or for general performance enhancement are outside the approved indication.
What does the PT-141 peptide do?
PT-141 activates melanocortin receptors in the brain, especially MC4R, and influences central processing linked to sexual desire and arousal. Human neuroimaging supports changes in relevant brain networks [19]. It does not work as a simple blood-flow drug, and response is not universal. Nausea, flushing, and headache were prominent in longer clinical follow-up [21].